Increasing evidence that the risks of rhAPC may outweigh its benefits
- 84 Downloads
Sir: The surveys by Kanji et al. and Bertolini et al. in this issue of “Intensive Care Medicine” are important in providing further insights into the increased bleeding risks associated with recombinant human activated protein C (rhAPC) in clinical practice [1, 2]. Following approval of rhAPC in 2001, early surveys and post-marketing studies suggested that the risk of bleeding during clinical use might be greater than was noted in the original phase-3 trial [Recombinant Human Activated protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial; 3, 4, 5, 6]. Even more concerning, two additional randomized controlled sepsis trials conducted post-approval have failed to show any significant benefit with rhAPC [7, 8]. In light of increasing experience with rhAPC, the critical care community should reconsider whether the bleeding risks associated with this agent outweigh its purported benefit.
Increased bleeding with rhAPC has been a consistent finding in all sepsis trials conducted to...
- 1.Kanji S, Perreault MM, Chant C, Williamson D, Burry L (2007) Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observation study. Intensive Care Med DOI 10.1007/s00134-007-0555-9
- 2.Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D (2007) Use of drotrecogin alfa (activated) in Italian intensive care units. The results of a nationwide survey. Intensive Care Med DOI 10.1007/s00134-007-0554-x
- 3.Steingrub J, Sanchez P, Zeckel M, Bates B, Qualy R (2003) Safety of drotrecogin alfa (activated): results of MERCURY, a retrospective multicenter observation study. Crit Care Med 31:A117Google Scholar
- 4.Tanzi M (2004) Use of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis: medical use evaluation by Novation, the supply company of VHA and UHC. NovationGoogle Scholar
- 8.Eisenberg P. Discontinuation of study F1K-MC-EVBP, investigation of the efficacy and safety of Drotrecogin alfa (activated) in pediatric severe sepsis (letter). http://www.fda.gov/medwatch/SAFETY/2005/xigris_dearhcp_4-21-05.htm. Accessed 5 July 2005
- 10.Eisenberg P. Important Drug Warning (letter) http://www.fda.gov/medwatch/SAFETY/2005/xigris_DHCP.htm. Accessed 5 July 2005
- 11.Vincent JL, Bernard GR, Beale R, Doig C, Putenson C, Dhainaut JF, Artigas A, Fumagelli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J, for the ENHANCE Study Group (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the Global Open-label Trial ENHANCE: further evidence for survival and safety. Crit Care Med 33:2266–2277PubMedCrossRefGoogle Scholar